Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).
- 출원번호 : 19350940
- 출원인 : MCLEAY, MATTHEW T.
- 특허번호 :
- IPC : A61K-031/409(2006.01);A61K-009/00(2006.01);A61K-031/02(2006.01);A61K-031/197(2006.01);A61K-031/198(2006.01);A61K-031/7056(2006.01);A61K-031/7068(2006.01);A61K-031/728(2006.01);A61K-045/06(2006.01);A61K-047/26(2006.01);A61P-031/14(2006.01);A61P-035/00(2006.01);A61P-035/04(2006.01);